Traws Pharma (TRAW) Expected to Release Quarterly Earnings on Thursday

Traws Pharma (NASDAQ:TRAW) is expected to be posting its Q3 2026 results on Thursday, November 12th. Analysts expect Traws Pharma to post earnings of ($0.21) per share and revenue of $2.71 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.18. On average, analysts expect Traws Pharma to post ($1.20) EPS for the current fiscal year and ($1.24) EPS for the next fiscal year.

Traws Pharma Stock Performance

NASDAQ:TRAW opened at $0.23 on Wednesday. The company has a market capitalization of $3.46 million, a price-to-earnings ratio of -0.13 and a beta of 1.67. Traws Pharma has a one year low of $0.22 and a one year high of $3.23. The stock has a 50-day simple moving average of $0.45 and a 200 day simple moving average of $1.10.

Wall Street Analyst Weigh In

A number of research analysts have commented on TRAW shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, August 26th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a research note on Tuesday, August 18th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $1.00.

Traws Pharma Company Profile

Traws Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral medicines for respiratory viral infections, including influenza and COVID-19. The company’s approach includes developing therapies designed to act against viral replication and host-cell pathways involved in disease progression. Traws Pharma’s pipeline includes zapnometinib, an investigational oral host-directed antiviral designed to inhibit the MEK signaling pathway, which may support treatment across multiple strains of influenza and coronaviruses.